Drugs / JY231
Trials 13 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 03 trials | ||||||
| Phase 0 | NCT06514768 | Jun 2024 → Jun 2026 overdue | B-cell acute lymphoblastic leukemia | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Recruiting | No outcome recorded |
| Phase 0 | NCT06243159 | Feb 2024 → Dec 2026 expected | autoimmune disease | Shanxi Bethune Hospital | Not yet recruiting | No outcome recorded |
| Phase 0 | NCT06045585 | Aug 2023 → Aug 2025 | B-cell non-Hodgkin lymphoma | Guangdong Second Provincial General Hospital | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT06675422 | Oct 2024 → Sep 2026 expected | systemic lupus erythematosus | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Recruiting | No outcome recorded |
| Phase not applicable9 trials | ||||||
| — | NCT07059169 | Aug 2025 → Dec 2026 expected | autoimmune disease | LiangZou | Recruiting | No outcome recorded |
| — | NCT07065279 | Jul 2025 → Dec 2027 expected | B-cell neoplasm | 920th Hospital of Joint Logistics Support Force of People's Liberation Army of China | Recruiting | No outcome recorded |
| — | NCT06940960 | May 2025 → Dec 2027 expected | B-cell acute lymphoblastic leukemia | Affiliated Hospital of Guangdong Medical University | Recruiting | No outcome recorded |
| — | NCT06902025 | Mar 2025 → Dec 2027 expected | — | He Huang | Not yet recruiting | No outcome recorded |
| — | NCT06887985 | Mar 2025 → Dec 2027 expected | autoimmune disease | He Huang | Not yet recruiting | No outcome recorded |
| — | NCT06879470 | Mar 2025 → Dec 2027 expected | B-cell non-Hodgkin lymphoma | He Huang | Not yet recruiting | No outcome recorded |
| — | NCT06797024 | Feb 2025 → Dec 2026 expected | autoimmune disorder of the nervous system | Tongji Hospital | Recruiting | No outcome recorded |
| — | NCT06689917 | Jan 2025 → Dec 2026 expected | B-cell non-Hodgkin lymphoma | Tongji Hospital | Recruiting | No outcome recorded |
| — | NCT06678282 | Sep 2023 → Sep 2026 expected | B-cell non-Hodgkin lymphoma | Shenzhen Genocury Biotech Co., Ltd. | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | JY231 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT07065279 ↗ |
| Known as | JY231 Injection | “Infusion of JY231 Injection by dose of 1-10 x10\^6 TU/kg、 1-5 x10\^7 TU/kg、 5-10 x10\^7 TU/kg” NCT06045585 ↗3“JY231 (JY231 injection)” NCT07059169 ↗ “Drug: JY231 Injection” NCT06689917 ↗ “Drug: JY231 Injection” NCT06678282 ↗ |
| Modality | Cell therapy | “in vivo Chimeric Antigen Receptor T-Cell (CAR-T) therapy” NCT06879470 ↗ |
| Route | Intravenous | “intravenous infusion” NCT06045585 ↗ |